Affimed to Collaborate with Merck to Evaluate AFM13 in Combination with KEYTRUDA for Patients with Hodgkin Lymphoma
January 25, 2016 at 05:02 AM EST
Affimed N.V. (Nasdaq: AFMD) announced today that it has entered into a clinical research collaboration in immuno-oncology with Merck ...